ELCC 2016 | Characterizing tumor-infiltrating lymphocytes in resectable early stage NSCLC
David Carbone
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses the characterization of tumor-infiltrating lymphocytes in resectable early stage non-small cell lung cancer (NSCLC) and the application of this understanding for the development of immunotherapy in early stage disease.
Related videos
1:21 ETOP 2020: what to expect
Sanjay Popat
1:48 Pharmacy perspective: pembrolizumab monotherapy 6 weekly dosing
Rob Duncombe
4:48 Minimizing the risk of steroid-induced hyperglycemia in NSCLC patients receiving immunotherapy
Islam Elkonaissi
0:54 SB8: a bevacizumab biosimilar for NSCLC
Martin Reck
2:19 The immunotherapy NSCLC revolution
Solange Peters
